Top

Published in:

01-06-2020 | Original article

Eotaxins and C–C chemokine receptor type 3 in Parkinson’s disease

Authors: Amir Moghadam-Ahmadi, Hossein Khorramdelazad, Gholamhossein Hassanshahi, Sasan Shahsavari, Ali Moadab, Alireza Vakilian

Published in: Acta Neurologica Belgica | Issue 3/2020

Abstract

Parkinson’s disease (PD) is one of the most common neuroinflammatory disorders and inflammatory processes seem to play an important role in the pathogenesis of PD. Chemokines as inflammatory mediators, which are involved in the recruitment of leukocytes, can play a role in the pathogenesis of PD. The aim of this study was to examine the serum level of eotaxins (CCL11, CCL24, and CCL26) and the expression of C–C chemokine receptor type 3 (CCR3) in patients with PD compared with healthy subjects. In this study, we measured the serum levels of CCL11, CCL24, and CCL26 with ELISA. In addition, gene and protein expression of CCR3 were measured by RT-PCR and flow cytometry techniques in PD patients (n = 30) and age- and sex-matched healthy subjects (n = 30). All patients suffering from PD were assessed clinically through Unified Parkinson’s Disease Rating Scale, Motor Examination (UPDRS ME). The results of this study showed that there was no significant alteration in the serum level of these chemokines and also their receptor among patients with PD and healthy subjects. No significant correlation was observed between the eotaxins serum levels and the clinical measures of PD severity. Based on the results, it can be concluded that eotaxins cannot be considered as appropriate targets for the diagnosis or treatment of PD.

Spillantini MG et al., α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci, 1998. 95(11): p. 6469–6473PubMedPubMedCentral

Petzinger GM et al (2013) Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease. Lancet Neurol 12(7):716–726PubMedPubMedCentral

Ouchi Y et al (2005) Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol 57(2):168–175PubMed

Scalzo P et al (2011) Serum levels of chemokines in Parkinson’s disease. Neuroimmunomodulation 18(4):240–244PubMed

Hanisch U-K, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10(11):1387PubMed

Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp Mol Med 38(4):333PubMed

Block ML, Hong J-S (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76(2):77–98PubMed

Perry VH, Nicoll JA, Holmes C (2010) Microglia in neurodegenerative disease. Nat Rev Neurol 6(4):193PubMed

Ramesh G, MacLean AG, Philipp MT (2013) Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediat Inflamm 2013:1–20

10.

Chemokine C (2002) Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 22:1067–1068

11.

Ahmadi Z et al (2016) An overlook to the characteristics and roles played by eotaxin network in the pathophysiology of food allergies: allergic asthma and atopic dermatitis. Inflammation 39(3):1253–1267PubMed

12.

Ponath PD et al (1996) Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 183(6):2437–2448PubMed

13.

Kitaura M et al (1996) Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem 271(13):7725–7730PubMed

14.

Rentzos M et al (2007) Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease. Acta Neurol Scand 116(6):374–379PubMed

15.

Reale M et al (2009) Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun 23(1):55–63PubMed

16.

Shimoji M et al (2009) CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson’s disease. Neurotox Res 16(3):318–328PubMed

17.

Parajuli B et al (2015) CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia 63(12):2274–2284PubMed

18.

König K et al (2015) Cytokine profiles in nasal fluid of patients with seasonal or persistent allergic rhinitis. Allergy Asthma Clin Immunol 11(1):26PubMedPubMedCentral

19.

Wittig HJ et al (1980) Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol 66(4):305–313PubMed

20.

Graham J (2002) Isolation of human polymorphonuclear leukocytes (granulocytes) from a leukocyte-rich fraction. Sci World J 2:1393–1396

21.

Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14(7):463PubMed

22.

Amor S et al (2010) Inflammation in neurodegenerative diseases. Immunology 129(2):154–169PubMedPubMedCentral

23.

Tran PB, Miller RJ (2003) Chemokine receptors: signposts to brain development and disease. Nat Rev Neurosci 4(6):444PubMed

24.

Michael B et al (2013) Post-acute serum eosinophil and neutrophil-associated cytokine/chemokine profile can distinguish between patients with neuromyelitis optica and multiple sclerosis; and identifies potential pathophysiological mechanisms—a pilot study. Cytokine 64(1):90–96PubMed

25.

Tanaka M et al (2008) Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 71(13):974–981PubMed

26.

Mena MA, García de J, Yébenes (2008) Glial cells as players in parkinsonism: the “good,” the “bad,” and the “mysterious” glia. Neuroscientist 14(6):544–560PubMed

27.

Dobbs R et al (1999) Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol Scand 100(1):34–41PubMed

28.

McGeer PL, McGeer EG (2008) The α-synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. Exp Neurol 212(2):235–238PubMed

29.

Selikhova M et al (2002) Impaired production of plasma interleukin-6 in patients with Parkinson’s disease. Bull Exp Biol Med 133(1):81–83PubMed

30.

Baba Y et al (2005) Alterations of T-lymphocyte populations in Parkinson disease. Park Relat Disord 11(8):493–498

31.

Xanthou G et al (2003) CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur J Immunol 33(8):2241–2250PubMed

Title: Eotaxins and C–C chemokine receptor type 3 in Parkinson’s disease
Authors: Amir Moghadam-Ahmadi
Hossein Khorramdelazad
Gholamhossein Hassanshahi
Sasan Shahsavari
Ali Moadab
Alireza Vakilian
Publication date: 01-06-2020
Publisher: Springer International Publishing
Published in: Acta Neurologica Belgica / Issue 3/2020
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-018-01061-8

At a glance: The STEP trials

Springer Medicine

Eotaxins and C–C chemokine receptor type 3 in Parkinson’s disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Primary creatine deficiency syndrome as a potential missed diagnosis in children with psychomotor delay and seizure: case presentation with two novel variants and literature review

Childhood acute disseminated encephalomyelitis: an Egyptian pilot study

Involvement of glutamate receptors of the paragigantocellularis lateralis nucleus in the pain modulatory effect of 17β-estradiol in male rats

Ipsilateral supranuclear lingual palsy due to caudal paramedian pontine infarction

Tibial motor and sural electrophysiological relationship in subjects without and patients with mild axonal peripheral neuropathy

An investigation on the effects of carbamazepine and sodium valproate on neuromuscular transmission